Background Influenza is an important cause of morbidity and mortality among older adults.
Even so, effectiveness of influenza vaccine for older adults has been reported to be lower …

Background The effectiveness of influenza vaccination in reducing influenza-related
hospitalizations among patients with COPD is not well described, and influenza vaccination uptake …

Background Ongoing assessment of influenza vaccine effectiveness (VE) is critical to inform
public health policy. This study aimed to determine the VE of trivalent influenza vaccine (TIV…

Background The 13-valent pneumococcal conjugate vaccine (PCV13) was recently shown to
be effective against PCV13-type invasive pneumococcal disease (IPD) and pneumococcal …

Background In Canada, 13-valent pneumococcal conjugate vaccine (PCV13) is recommended
in childhood, in individuals at high risk of invasive pneumococcal disease (IPD) and in …

Background Consideration of cost determinants is crucial to inform delivery of public
vaccination programs. Objectives To estimate the average total cost of laboratory‐confirmed …

Objective(s) In the context of age- and risk-based pneumococcal vaccine recommendations
in Canada, this study presents updated data from active surveillance of pneumococcal …

Background Respiratory syncytial virus (RSV) disease in older adults is undercharacterized.
To help inform future immunization policies, this study aimed to describe the disease …

Background Pneumococcal community acquired pneumonia (CAP Spn ) and invasive
pneumococcal disease (IPD) cause significant morbidity and mortality worldwide. Although …

Background The Serious Outcomes Surveillance (SOS) Network was established to monitor
seasonal influenza complications among hospitalized Canadian adults and to assess the …